NEW YORK — Biopharma company Epizyme said Wednesday that it has launched a collaboration with Quest Diagnostics to provide mutation testing for lymphoma patients.
Called the EZH2Now Testing Program, the initiative aims to improve patient access to EZH2 mutation testing for patients with relapsed or refractory follicular lymphoma.
EZH2 is an epigenetic regulator of B-cell identity and is involved in normal B-cell biology and the pathogenesis of follicular lymphoma. It is an emerging drug target, and while oncogenic dependence on EZH2 can occur regardless of mutation status, single-gene testing could help physicians better characterize their patients' cancer.
Patients who qualify for the EZH2Now Testing Program will receive testing services at no cost.
"We are committed to broadening access to diagnostic insights for patients and providers everywhere," Kristie Dolan, general manager, oncology franchise at Quest, said in a statement. "Our participation in the EZH2Now Testing Program not only delivers on this goal, but also highlights Quest Diagnostics’ commitment to innovations in oncology and advanced diagnostics that improve patient care, as well as our deep specialization in hematopathology."
Financial and other terms of the agreement were not disclosed.